2023
Impact of sarcopenia on outcomes in surgical patients: a systematic review and meta-analysis
Knoedler S, Schliermann R, Knoedler L, Wu M, Hansen F, Matar D, Obed D, Vervoort D, Haug V, Hundeshagen G, Paik A, Kauke-Navarro M, Kneser U, Pomahac B, Orgill D, Panayi A. Impact of sarcopenia on outcomes in surgical patients: a systematic review and meta-analysis. International Journal Of Surgery 2023, 109: 4238-4262. PMID: 37696253, PMCID: PMC10720826, DOI: 10.1097/js9.0000000000000688.Peer-Reviewed Original ResearchImpact of sarcopeniaPostoperative outcomesComplication occurrenceSurgical patientsSystematic reviewHospital stayPrognostic valueSubgroup analysisSurvival rateClavien-Dindo classification systemImportance of sarcopeniaFrequency of complicationsPoor postoperative outcomesInflammatory bowel diseaseSignificant predictorsHigh-quality studiesMeta-Analyses (PRISMA) guidelinesProspective study designPubMed/MEDLINESkeletal muscle massPreferred Reporting ItemsLength of operationLower survival rateSarcopenic patientsPerioperative risk
2021
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
Apostolidi M, Vathiotis IA, Muthusamy V, Gaule P, Gassaway BM, Rimm DL, Rinehart J. Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes. Cancer Research 2021, 81: 4346-4359. PMID: 34185676, PMCID: PMC8373815, DOI: 10.1158/0008-5472.can-20-4190.Peer-Reviewed Original ResearchMeSH KeywordsActive Transport, Cell NucleusAnimalsBiomarkers, TumorCarrier ProteinsCell Line, TumorCollagenCyclic N-OxidesDrug CombinationsGenome, HumanHumansIndolizinesLamininMCF-7 CellsMembrane ProteinsMiceNeoplasm InvasivenessNeoplasm TransplantationNeoplasmsOxidation-ReductionPhenotypePhosphorylationProtein IsoformsProteoglycansProteomicsPyridazinesPyridinium CompoundsPyrrolesPyruvate KinaseThyroid HormonesTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerPyruvate kinase M2TEPP-46Breast cancerAggressive breast cancer cell phenotypesCharacteristic nuclear staining patternAggressive breast cancer subtypeAggressive breast cancer phenotypeBreast cancer cell phenotypeCDK inhibitor dinaciclibCombination of dinaciclibLack of biomarkersEffective therapeutic approachBreast cancer phenotypeBreast cancer subtypesCancer phenotypePhosphorylation of PKM2Cyclin-dependent kinase (CDK) pathwayMouse xenograft modelAggressive cancer phenotypeNuclear staining patternLower survival rateImpaired redox balancePrognostic valueCancer cell phenotype
2020
Neutropenic Enterocolitis: Clinical Features and Outcomes.
Abu-Sbeih H, Ali F, Chen E, Mallepally N, Luo W, Lu Y, Foo W, Qiao W, Okhuysen P, Adachi J, Hachem R, Altan M, Jenq R, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Diseases Of The Colon & Rectum 2020, 63: 381-388. PMID: 31842164, DOI: 10.1097/dcr.0000000000001548.Peer-Reviewed Original ResearchConceptsMD Anderson Cancer CenterNeutropenic enterocolitisGranulocyte colony-stimulating factorAnderson Cancer CenterCancer CenterColony-stimulating factorMucosal injuryClinical featuresSurvival rateTexas MD Anderson Cancer CenterConcomitant systemic infectionImmunosuppressive therapy useDuration of neutropeniaRetrospective cohort studyAbsolute neutrophil countCox regression analysisComprehensive cancer centerLower survival rateAbdominal symptomsEnterocolitis diagnosisEnterocolitis symptomsNeutropenia onsetPneumatosis intestinalisCohort studyColonic perforation
2019
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer
Hasan N, Ahuja N. The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer. Cancers 2019, 11: 1859. PMID: 31769422, PMCID: PMC6966483, DOI: 10.3390/cancers11121859.Peer-Reviewed Original ResearchATP-dependent chromatinChromodomain helicase DNA-binding proteinStem cell maintenanceDNA-binding proteinsAberrant chromatin modificationsChromatin modificationsChromatin structureMain subfamiliesCell maintenanceEpigenetic dysregulationChromatinDifferent cancer typesSwitch/Genomic alterationsCritical roleSmall moleculesFrequent mutationsCancer typesChromosomal aberrationsEmerging RoleComplexesLower survival rateAggressive cancerPancreatic cancerMechanistic studies223TiP EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Petrylak D, Rosenberg J, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. 223TiP EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. Annals Of Oncology 2019, 30: ix75-ix76. DOI: 10.1093/annonc/mdz425.014.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaSeattle GeneticsUrothelial carcinomaDisease progressionCohort 1Microtubule-disrupting agent monomethyl auristatin EDay 1Prior platinum-containing chemotherapyClinical care optionsRadiological disease progressionSafety/tolerabilityTumour response statusPlatinum-containing chemotherapyPhase 2 studyPhase 3 trialPhase III trialsSanofi-AventisPlatinum-based chemotherapyCurrent treatment optionsIndependent central reviewHumanized monoclonal antibodyMonomethyl auristatin ELower survival rateMedian DoRPrimary endpointYiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung T, Qu Z, Chen Z, Adelson D, Lin L. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry Part A 2019, 97: 70-77. PMID: 31411813, PMCID: PMC7004076, DOI: 10.1002/cyto.a.23869.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR mutationsGrowth factor receptor tyrosine kinase inhibitorsDrug resistanceReceptor tyrosine kinase inhibitorsEGFR TKI-resistant cellsEGFR-TKI resistanceNew treatment strategiesGefitinib-induced apoptosisAnti-cancer effectsLower survival rateWestern blot analysisMonths treatmentMost patientsNSCLC patientsCell cycle arrestTreatment strategiesHigh incidenceMortality rateSurvival rateCancer leadFlow cytometryPatientsResistant cellsKinase inhibitors
2017
Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model
Huleihel L, Sellares J, Cardenes N, Álvarez D, Faner R, Sakamoto K, Yu G, Kapetanaki MG, Kaminski N, Rojas M. Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2017, 313: l92-l103. PMID: 28385811, PMCID: PMC5538868, DOI: 10.1152/ajplung.00323.2016.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkersBleomycinBone Marrow CellsCollagenCytokinesDisease Models, AnimalFemaleGene Expression RegulationGene Regulatory NetworksHumansInterleukin-6Leukocyte Common AntigensLung InjuryMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice, Inbred C57BLMicroRNAsRNA, MessengerSurvival AnalysisTransduction, GeneticTransfectionWeight LossConceptsBone marrow-derived mesenchymal stem cellsMesenchymal stem cellsLung fibrosisLate administrationBleomycin modelMiR-154Different preclinical modelsStem cellsCD45-positive cellsMurine bleomycin modelMarrow-derived mesenchymal stem cellsInitial weight lossLower survival rateAshcroft scoreLung injuryBleomycin instillationFibrotic changesCytokine expressionMice groupsLung tissueOH-prolinePreclinical modelsProtective effectTreatment groupsSurvival rate
2010
Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer
Zhu Y, Fariña JB, Meshack S, Santoveña A, Patel S, Oliva A, Llabrés M, Hodsdon ME, Booth CJ, Dannies PS. Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine 2010, 37: 430-439. PMID: 20960164, DOI: 10.1007/s12020-010-9333-5.Peer-Reviewed Original ResearchConceptsHuman ovarian cancerOvarian cancerPeritoneal cavityMouse modelTumor cell injectionImmunodeficient SCID miceGrowth hormone releaseHuman ovarian cancer cellsAnti-tumor effectsOvarian cancer cellsReplication-deficient adenovirusLower survival rateLiver metastasesMedian survivalControl miceLung metastasesIntraperitoneal injectionPeritoneal fibrosisLiver toxicitySCID miceHormone releaseHepatocellular changesSurvival rateCell injectionGrowth hormone
2004
Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation
Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. Transplantation 2004, 78: 580-583. PMID: 15446318, DOI: 10.1097/01.tp.0000129797.30999.69.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionHepatocellular carcinomaHCV/Liver transplantationVirus infectionChronic hepatitis C virus (HCV) infectionSurvival rateChronic HCV infectionOrthotopic liver transplantationOutcomes of patientsOrgan Sharing dataHCC recurrence rateOverall survival rateLower survival rateHCV groupLT patientsHCV infectionHCC recurrencePatient survivalRecurrence rateUnited NetworkMean agePotential contraindicationsHCC group
2003
Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?
Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, O’Connor C. Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? American Heart Journal 2003, 145: 758-767. PMID: 12766731, DOI: 10.1016/s0002-8703(02)94818-0.Peer-Reviewed Original ResearchMeSH KeywordsCoronary DiseaseFemaleFluorodeoxyglucose F18Heart FailureHumansMaleMyocardial RevascularizationProspective StudiesRadiopharmaceuticalsRetrospective StudiesSurvival RateThallium RadioisotopesTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsSignificant coronary artery diseaseCoronary artery diseaseLong-term mortalityArtery diseaseSurvival rateHeart failureTreatment strategiesImpaired left ventricular functionLong-term mortality ratesIschemic heart failureLeft ventricular functionIntermediate survival ratesNuclear imaging studiesLack of randomizationLower survival rateEjection fractionVentricular functionViable myocardiumReferral biasStudy protocolTreatment allocationLarge cohortPrognostic studiesMortality ratePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply